Novartis' Foray Into Academia
Executive SummaryNovartis' decision to relocate its discovery operation to Cambridge, MA has garnered considerable attention for what it says about the decline of Europe's competitiveness in the pharmaceutical industry and the increasing attraction of the Boston area for drug and biotech firms. But perhaps even more significant is what the transatlantic move reveals about Novartis' intention to fundamentally change its approach to drug discovery research and what that transformation may mean for the industry in general.
You may also be interested in...
Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.
Consultant John McKay encourages device makers to ask questions of the US FDA’s inspection team during a facility audit. Check out his advice here.